Skip to main content
. 2022 Oct 11;8:114. doi: 10.1038/s41523-022-00479-x

Fig. 4. Forest plot of overall survival by subgroup after PSM.

Fig. 4

AI aromatase inhibitor; Dx diagnosis; ECOG PS Eastern Cooperative Oncology Group performance status; ND not documented; PAL palbociclib; PSM propensity score matching. *Bone-only disease was defined as metastatic disease in the bone only. Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.